Biocryst Pharmaceuticals reported $72.21M in Gross Profit on Sales for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Alnylam Pharmaceuticals ALNY:US USD 223.19M 39.18M
Biocryst Pharmaceuticals BCRX:US USD 72.21M 6.93M
Chugai Pharma 4519:JP JPY 156.19B 399M
Daiichi Sankyo 4568:JP JPY 242.71B 37.19B
Gilead Sciences GILD:US USD 5.65B 829M
GlaxoSmithKline GSK:LN GBP 5.44B 650M
Glaxosmithkline GSK:US GBP 5.44B 650M
Intra Cellular Therapies ITCI:US USD 66.02M 15.09M
Karyopharm Therapeutics KPTI:US USD 35.16M 3.58M
Neurocrine Biosciences NBIX:US USD 381.8M 8.4M
Ptc Therapeutics PTCT:US USD 203.12M 47.23M
Regeneron Pharmaceuticals REGN:US USD 2.62B 58.3M
Sarepta Therapeutics SRPT:US USD 190.32M 5.38M
Ultragenyx Pharmaceutical RARE:US USD 82.07M 999K
Vertex Pharmaceuticals VRTX:US USD 2.04B 110.5M
YTE INCY:US USD 774.02M 92.14M